I have been reading up on this stock over recent times. Most of...

  1. 10 Posts.
    I have been reading up on this stock over recent times. Most of what I have read paints the product and the company in an extremely positive light. However, I have come across a couple of comments that have raised some slight concerns and am interested in others thoughts.

    1. It appears that 'best practice' in Australia dictates that doctors do not prescribe combination opiods. Morphine and oxycodone are different molecules but both are opiod derivatives. Does anyone know if 'best practice' in the US and Europe is different and doctors do prescribe combination opiods? Agreement with Actavis suggests they are confident that the product will be in demand.

    2. Whilst I understand that the fixed 3:2 ratio is patented, what is to stop the a person taking the two drugs separately in that ratio. From what I have read that seems a cheaper option?

    Thanks

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.